Risks

Negative interest coverage and modest net debt versus EBITDA increase refinancing sensitivity, leaving EVGN less resilient than better-capitalized ag-biotech peers if funding conditions tighten.

Days sales outstanding above 100 and a 33-day cash conversion cycle indicate working-capital drag, which can constrain cash generation more than in faster-collecting peers.

A current ratio above 3.5 supports near-term liquidity, but the absence of positive FCF visibility keeps EVGN more exposed than peers with self-funding operating models.

Negative debt-to-equity reflects an atypical capital structure, which can amplify volatility versus peers with cleaner balance sheets when market access or earnings momentum weakens.

Opportunities

Strong current and quick ratios provide liquidity flexibility, giving EVGN more room than leveraged peers to bridge commercialization cycles and support customer adoption.

Net debt to EBITDA near 0.6 suggests manageable leverage, which can preserve strategic optionality versus more indebted peers if operating performance improves.

Inventory days remain moderate relative to many specialty-input peers, supporting working-capital discipline and reducing the risk of cash being tied up in stock.

If receivables collection improves from elevated DSO levels, EVGN could convert revenue into cash more efficiently than peers with similarly long sales cycles.

Overall Score

EVGN’s forward positioning is balanced by solid liquidity and manageable leverage, but weak coverage and working-capital drag limit its ability to outperform better-capitalized peers.